Praxis Precision Medicines, Inc.
PRAX| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Point72 Steve Cohen | 992K | $292.48M | NEW |
| Citadel Ken Griffin | 139K | $41.00M | NEW |
| Marshall Wace | 69K | $20.41M | NEW |
| Renaissance Technologies Jim Simons (founder) | 66K | $19.52M | NEW |
| D.E. Shaw David Shaw | 47K | $13.99M | NEW |
| Hussman Investment Trust John Hussman | 8K | $2.48M | NEW |
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Earnings calendar coming soon. Subscribe to get notified when PRAX reports next.
Get earnings alerts →